<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: The use of patient reported outcome measures to support routine <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) care is not widespread and suggests that existing questionnaires lack relevance to day-to-day decisions or are too cumbersome to administer </plain></SENT>
<SENT sid="1" pm="."><plain>We developed a simple, generic tool for capturing disease control from the patient's perspective to address these barriers </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Development based on literature review, patient focus groups/interviews and a steering group, defining a limited set of generic questions </plain></SENT>
<SENT sid="3" pm="."><plain>The 'IBD-Control' questionnaire comprises 13 items plus a visual analogue scale (VAS) (0-100) </plain></SENT>
<SENT sid="4" pm="."><plain>Prospective validation involved baseline completion of IBD-Control, quality of life (QoL) questionnaire (UK-IBD-Q), EuroQol (EQ-5D), Hospital <z:hpo ids='HP_0000739'>Anxiety</z:hpo> and <z:hpo ids='HP_0000716'>Depression</z:hpo> Score; and clinician assessment (blinded to questionnaire; recording Harvey-Bradshaw Index or Simple Clinical <z:hpo ids='HP_0002583'>Colitis</z:hpo> Activity Index; Global Clinician Rating; treatment outcome) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: 299 patients returned baseline surveys (<z:hpo ids='HP_0100280'>Crohn's disease</z:hpo>, n=160; <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, n=139) and 138 attended for repeat visits </plain></SENT>
<SENT sid="6" pm="."><plain>Completion time (mean; SD): 1 min 15 s; 25 s; Internal consistency: Cronbach's α for <z:hpo ids='HP_0000001'>all</z:hpo> 13 items (0.85); for subgroup of eight questions ('IBD-Control-8'; 0.86) </plain></SENT>
<SENT sid="7" pm="."><plain>Strong correlation between IBD-Control-8 and IBD-Control-VAS (r=0.81) </plain></SENT>
<SENT sid="8" pm="."><plain>Test-retest reliability (2 week repeat): intra-class correlation=0.97 for IBD-Control-8 and 0.96 for IBD-Control-VAS </plain></SENT>
<SENT sid="9" pm="."><plain>Construct validity: Moderate-to-strong correlations between IBD-Control-8 and IBD-Control-VAS versus activity indices, UK-IBD-Q and EQ-5D (utility) with r values 0.52-0.86 </plain></SENT>
<SENT sid="10" pm="."><plain>Discriminant validity (mean instrument scores for remission, mild, moderate or severe): p&lt;0.001 (analysis of variance (ANOVA)) </plain></SENT>
<SENT sid="11" pm="."><plain>Sensitivity to change: Effect sizes: 0.76-1.44 </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: The IBD-Control is a rapid, reliable, valid and sensitive instrument for measuring overall disease control from the patient's perspective </plain></SENT>
<SENT sid="13" pm="."><plain>Unlike existing patient reported outcome measures, its simplicity, ease-of-use and generic applicability make it a candidate for supporting routine care </plain></SENT>
</text></document>